$CMPS is giving a GREAT IPO LONG opportunity today
Updated
IPO intraday trading strategy idea
COMPASS Pathways is developing a drug treatment for treatment-resistant depression [TRD].
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $25,00;
stop-loss — $20,00
information about take-profit will be later
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
COMPASS Pathways is developing a drug treatment for treatment-resistant depression [TRD].
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $25,00;
stop-loss — $20,00
information about take-profit will be later
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Trade closed manually
$29,00
More information: fondexx.pro/
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
!!! Join our trader's chat !!!
Here ==> t.me/fndxworld
We build a cozy community of professional traders
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.